Actuate-linked trial of 9-ING-41 plus carboplatin in salivary gland cancer posts results

The week's single notable update involves a Phase 2 study of 9-ING-41 in salivary gland carcinoma, sponsored by an individual investigator with Actuate Therapeutics as collaborator.

• 9-ING-41, a GSK-3β inhibitor, combined with carboplatin (and pembrolizumab added in a later study part) for advanced, metastatic or recurrent salivary gland carcinoma, including adenoid cystic carcinoma, is listed as "active not recruiting," with results first posted 2026-08-07. The study (NCT05010629) reached primary completion on 2025-02-14 (actual), with estimated study completion on 2027-04-12.¹ Enrollment was 32 participants (actual) across a non-randomized, single-group Phase 2 design.¹ Actuate Therapeutics is described as supporting the research by providing the study drug and funding some trial logistics beyond standard of care.¹ The FDA has not approved 9-ING-41 for any disease,¹ while carboplatin is already approved by the FDA for many cancer types and is used to treat salivary gland cancers.¹